Olverembatinib dimesylate

• CAT Number: R061450
• CAS Number: 1421783-64-3
• Molecular Formula: C31H35F3N6O7S2
• Molecular Weight: 724.77
• Purity: ≥95%
• Synonyms: methanesulfonic acid;4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide
• InChI: InChI=1S/C29H27F3N6O.2CH4O3S/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38;2*1-5(2,3)4/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36);2*1H3,(H,2,3,4)
• InChIKey: LEVIGHXVOVROGW-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CC5=C(NN=C5)N=C4.CS(=O)(=O)O.CS(=O)(=O)O

Olverembatinib dimesylate (Cat No.:R061450) is a potent, orally bioavailable third-generation BCR-ABL tyrosine kinase inhibitor developed to overcome resistance from mutations such as T315I in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). By targeting both wild-type and mutant BCR-ABL, it effectively suppresses leukemic cell proliferation and survival. The dimesylate salt improves solubility and pharmacokinetic properties. Olverembatinib dimesylate is being investigated clinically for patients resistant or intolerant to prior TKIs, while also serving as a valuable research tool for studying resistance mechanisms and therapeutic strategies.